Why would I need the dictionary? I'm fairly sure, as I stated before, that you did spell it correctly.
Any validity to your statement about the .88 options relies on history going pretty far back. Titan has always been a development company, and will remain so until they either start selling a product or get bought out. When they became a publicly traded company (Sept 2014, I believe) they followed the standard model of any publicly traded development stage company - when they need to pay the bills, they sell more shares, hence dilution. It is a fact of life for virtually any publicly traded development stage company; the entire business model is built around it and that is why dilution is a fact of life for such an organization. The big difference now is that we have a source of funding for some period of time without additional dilution. Just gotta hit a few milestones. The first milestone had a four month window, and we hit it in one day. That sounds very competent to me, but far from how you seem to characterize things.
On your comment about the delay of going back to the laboratory, I can only say that you appear to have virtually no experience in development of a medical device. They have completed the design of the new tools. They must now evaluate safety and efficacy of the new design, which logically occurs in a lab environment. This is not a setback or a delay, this is the development process as it pertains to a medical device proceeding toward the regulatory approval phase.
We believe that our next subsequent milestone is due in October. I would guess there is a fair chance that successful evaluation and testing of these tools, presumably with proper integration into the overall system design, could well be the October milestone. Validation plans are most likely already written, and just need to be executed in the lab, followed by writing up the reports. Two or three weeks of testing at most, allow another week for finalizing the reports (which will be written as the testing occurs) and getting the appropriate approvals. We could potentially meet our next milestone and receive the next payment before Labor Day... in which case, this would represent a delay of negative 8 weeks, because that would be substantially ahead of schedule.
We don't know their full schedule; we know much less about it than I would like to know. Reasonable assumptions would put the schedule somewhere near the Mazor acquisition model, or more compressed given how far advanced the overall system development is and the huge value for MDT of getting this product to the market. Software development is a further unknown to us investor peons, but whether they adhere to the old Waterfall model, or Scrum, or Agile... any and all of them first create a plan with a schedule, and they know what the schedule is.
We all know this is an absolute playground for the shorts; short volume has averages 34.5% over the past two weeks and barring any SUBSTANTIAL news, we will probably sit down here under their (your) shared "control" until the conflagration hits. That will be so much fun!
Message in reply to:
You might want to check a French English dictionary.
If you don’t think there’s any validity to what I’m saying about the 88 cent options, then you might want to look at what happened to the price per share when McNally was brought on board with options for around $15, and also what happened when they were subject to the reprice to 3 40. In each case they were followed by massive delays and significant dilution.
Just look at today’s press release to find more proof. They have to go back to the laboratory stages now. They are way delayed.
Longs are going to get crushed after this conference.
But hey, they will likely put a new video out. Maybe they can use a turkey breast this time? It would be a fitting symbol as to the capacity of management.
